"Promising New Drug Offers Hope in the Fight Against Alzheimer's Disease"
Scientists are set to unveil crucial findings on a new drug, donanemab, which has shown promising results in slowing the progression of Alzheimer's disease. This drug, along with another called lecanemab, are the first to successfully delay the relentless progression of the disease by targeting proteins known as tau and amyloid. The initial trial results have been hailed as a potential gamechanger in the battle against Alzheimer's, offering hope for the estimated 720,000 people in the UK affected by the disease. However, systemic changes are needed for widespread availability, and it may take 12 to 18 months for UK regulators to potentially license donanemab as safe.